Table 1 Patient characteristics and descriptive statistics
Variable | All patients (n = 128) |
|---|---|
Median Age, years (range) | 61.0 (34.0–87.0) |
Sex, n (%) | |
 Male | 103 (80.5) |
 Female | 25 (19.5) |
Median Body Mass Index (BMI), Kg/m2 (range) | 24.7 (17.1–35.9) |
Laterality, n (%) | |
 Right | 60 (46.9) |
 Left | 68 (53.1) |
Clinical Symptoms, n (%) | |
 Hematuria | 53 (41.4) |
 Osphyalgia | 17 (13.3) |
 Paraneoplastic Syndrome  (Fever, Anemia, Hypercalcemia, Emaciation) | 18 (14.1) |
 Asymptomatic | 55 (42.9) |
MaximumTumor Size, cm (range) | 7.4 (2.7~19.0) |
Perirenal Fat Invasion, n (%) | |
 Yes | 52 (40.6) |
 No | 76 (59.4) |
Tumor Necrosis, n (%) | |
 Yes | 33 (25.8) |
 No | 95 (74.2) |
pN+, n (%) | |
 Yes | 9 (7.0) |
 No | 121 (93.0) |
Pathological Type, (%) | |
 Clear Cell Carcinoma | 126 (98.4) |
 Chromophobe Cell Carcinoma | 1 (0.8) |
 Type II Papillary Cell Carcinoma | 1 (0.8) |
Fuhrman Grade (Clear Cell Carcinoma), n (%) | |
 G1 | 7 (5.6) |
 G2 | 46 (36.5) |
 G3 | 52 (41.3) |
 G4 | 21 (16.6) |
Sarcomatoid Differentiation, n (%) | |
 Yes | 26 (20.8) |
 No | 102 (79.2) |
Friable RVTT, n (%) | |
 Yes | 23 (18.0) |
 No | 105 (82.0) |
Median Bleeding Volume, ml (range) | 150 (30~4000) |
Median Volume of Blood Transfusion, ml (range) | 1200 (200~4500) |
Postoperative Adjuvant Therapy, n (%) | |
 Cytokine or Targeted Therapy | 60 (46.9) |
 Active surveillance | 68 (53.1) |
Postoperative Local Recurrence/Metastasis, n (%) | |
 Lung Metastasis | 39 (30.5) |
 Bone Metastasis | 7 (5.5) |
 Local Recurrence | 4 (3.1) |
 Thyroid Metastasis | 2 (1.6) |
 Brain Metastasis | 1 (0.8) |
 Scalp Metastasis | 1 (0.8) |
 Abdominal Wall Metastasis | 1 (0.8) |
 Lymph Node Metastasis | 1 (0.8) |
 Multiple Organ Metastasis | 3 (2.3) |